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A metabolomic approach to identifying platinum
resistance in ovarian cancer
Laila M Poisson1,2,3, Adnan Munkarah3,4, Hala Madi4, Indrani Datta1,2, Sharon Hensley-Alford2,3, Calvin Tebbe4,
Thomas Buekers4, Shailendra Giri3,5 and Ramandeep Rattan3,4*

Abstract
Background: Acquisition of metabolic alterations has been shown to be essential for the unremitting growth of
cancer, yet the relation of such alterations to chemosensitivity has not been investigated. In the present study our
aim was to identify the metabolic alterations that are specifically associated with platinum resistance in ovarian
cancer. A global metabolic analysis of the A2780 platinum-sensitive and its platinum-resistant derivative C200
ovarian cancer cell line was performed utilizing ultra-high performance liquid chromatography/mass spectroscopy
and gas chromatography/mass spectroscopy. Per-metabolite comparisons were made between cell lines and an
interpretive analysis was carried out using the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic library
and the Ingenuity exogenous molecule library.
Results: We observed 288 identified metabolites, of which 179 were found to be significantly different (t-test p < 0.05)
between A2780 and C200 cells. Of these, 70 had increased and 109 had decreased levels in platinum resistant C200
cells. The top altered KEGG pathways based on number or impact of alterations involved the cysteine and methionine
metabolism. An Ingenuity Pathway Analysis also revealed that the methionine degradation super-pathway and cysteine
biosynthesis are the top two canonical pathways affected. The highest scoring network of altered metabolites was
related to carbohydrate metabolism, energy production, and small molecule biochemistry. Compilation of KEGG
analysis and the common network molecules revealed methionine and associated pathways of glutathione synthesis
and polyamine biosynthesis to be most significantly altered.
Conclusion: Our findings disclose that the chemoresistant C200 ovarian cancer cells have distinct metabolic alterations
that may contribute to its platinum resistance. This distinct metabolic profile of platinum resistance is a first step
towards biomarker development for the detection of chemoresistant disease and metabolism-based drug targets
specific for chemoresistant tumors.
Keywords: Metabolomics, Ovarian cancer, Platinum resistance, A2780, C200, Methionine metabolism

Background
Ovarian cancer is responsible for the highest mortality
of all cancers of the female reproductive system. It accounts for approximately 3% of all cancers in women
and is the fifth leading cause of cancer related death
among women in the United States [1]. Ovarian cancers
are generally sensitive to chemotherapy and often initially respond well to standard primary treatment with
surgery and first-line platinum and taxane-based
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chemotherapy. However, approximately 70% of the patients experience disease relapse within 2 years of the
initial treatment. Of these, only a few benefit from subsequent therapies using a platinum and taxane combination. Patients with a short time to disease progression
and with no benefit to further platinum-based therapy are
classified as having platinum-resistant disease, whereas
those with long-lasting response to primary treatment
and/or response to second-line platinum-based therapy
are said to have platinum-sensitive disease. Even though
the presence or development of platinum resistance is a
major obstacle in successful ovarian cancer treatment,
platinum therapy is still the principal treatment for recurrent tumors [2].
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The antitumor activity of platinum has been shown to
be due to the formation of intra-strand DNA adducts,
which are irreparable and will eventually lead to cell
apoptosis [3]. Additionally, cisplatin, a commonly used
platinum-compound chemotherapy, is known to induce
oxidative stress and endoplasmic reticulum stress, but
the extent to which these pathways contribute to cell
death is not yet established [4,5]. Platinum resistance has
been attributed to reduced drug accumulation, improved
drug efflux, drug inactivation, enhanced DNA repair ability and upregulation of anti-apoptotic or other survival
genes [6,7]. While advancements have been made in understanding the molecular deregulation underlying chemoresistance, these have not translated into clinical
applications to enhance the therapeutic outcome of platinum resistant tumors. Therefore, strategies addressing
the identification of chemoresistant tumors that can be
directly translated to clinic are required.
Metabolomics is a new discipline which evaluates diverse metabolite concentrations in biological specimens
to gain insight into the ongoing metabolism. Metabolites
are the end product of various metabolic pathways and
may have application as biomarkers for cancer diagnosis,
prognosis, and therapeutic evaluation [8]. Apart from revealing diagnostic and prognostic biomarkers, this profile of cell functioning at the metabolite level will help
obtain an elementary understanding of the process of
carcinogenesis and chemoresistance that may provide
opportunities for early diagnosis and treatment.
Recent metabolomic based studies in ovarian cancer
have been applied to the screening of urine, plasma, and
tumor tissue from ovarian cancer patients and control
populations [9-14]. These studies have endeavored to
discriminate between healthy and ovarian cancer patients [9-11], profile malignant and borderline ovarian
tumors [10], and detect recurrent tumors [12,14]. All of
these studies clearly demonstrate that metabolomic profiles in the urine, plasma, or tumor tissue can distinctly
separate healthy women from those with benign or malignant ovarian tumors, indicating that the science of
metabolomics can be successfully applied for ovarian
cancer characterization and identification.
Since all chemotherapeutic drugs are metabolically
processed, it can be extrapolated that metabolism plays a
vital role in chemoresponse of the tumors. Cell death
whether by apoptosis or necrosis requires energy from the
cell and involves regulation by various metabolic enzymes.
Targeting of metabolic enzymes from key metabolic pathways, like glycolysis [15], fatty acid synthesis [16], and glucose transport [17], have been shown to enhance the
cytotoxicity of various chemotherapeutic agents and
radiotherapy. Moreover, cisplatin treatment has recently
been shown to induce intracellular metabolic changes
[18]. Thus, it can be postulated that chemoresistant tumor
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cells will have specific altered metabolism compared to
chemosensitive tumor cells that could be detected by
comparing their metabolites.
We designed our metabolomics-based study to identify
metabolite variations that distinguish between platinum
resistant and sensitive ovarian cancer cells. By using
platinum sensitive A2780 and resistant C200 ovarian
cancer cell lines, we are able to show that metabolite alterations can clearly separate the cells based on their
platinum sensitivity. We identified significant metabolite
variations in 6 different metabolic pathways participating
in various signaling networks, with methionine metabolism and its associated metabolites being the centrally affected pathway.

Methods
Cell lines

A2780 and C200 cell lines were a kind gift from Dr.
Thomas Hamilton, Fox Chase Cancer Center, PA. The cell
lines were maintained in Roswell Park Memorial Institute
media (HyClone-ThermoScientific; Waltham, MA) supplemented with 10% fetal bovine serum (BioAbChem;
Ladson, SC) and insulin. For preparation of cells, cells
were grown for 48 hours in insulin free media. Ten million
cells were counted, washed with phosphate buffered saline
and snap frozen.
Metabolite assessment

Metabolomic profiling analysis was performed by Metabolon Inc. (Durham, NC) as previously described [19-22].
Briefly, sample preparation was conducted using an aqueous methanol extraction and the resulting extract were analyzed by ultra-performance liquid chromatography/mass
spectroscopy (positive and negative modes) and gas chromatography/ mass spectroscopy. Raw data were extracted,
peak-identified and quality control processed using Metabolon’s hardware and software. Compounds were identified
by comparison to library entries of purified standards or recurrent unknown entities based on 3 criteria: retention
index within a narrow retention index window of the proposed identification, nominal mass match to the library +/−
0.2 atomic mass units, and the mass spectroscopy/mass
spectroscopy forward and reverse scores between the experimental data and authentic standards.
Data analysis

To control for sample concentration, each metabolite intensity value was standardized as a ratio against the
Bradford protein measure for that sample. Missing values
which indicate a limit of detection by the mass spectrometer were replaced with a small value (one half the study
minimum) for analysis. The data were visualized by plotting the first and second components of a partial least
squares discriminant analysis (PLS-DA) model. A z-score
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plot was generated by plotting each metabolite intensity of
the resistant C200 cells relative to the mean and standard
deviation of the sensitive (A2780) cells. A one-unit change
indicated a one standard deviation change in intensity
away from the A2780 mean. Each observation represents
1 point on this z-score plot. The observations were organized by metabolites (rows) within super-pathway and
sub-pathway. Metabolite intensities were compared between lines by a two-sample t-test per metabolite allowing
for unequal variance on a log2 scale. Significant metabolites (at p < 0.01) were selected for inclusion in the heatmap. Metabolites (rows) were ordered first by superpathway and then by direction of change. The columns
(samples) are ordered by hierarchical clustering using
Pearson correlation and complete linkage. Overrepresentation of changed molecules within super-pathway and
sub-pathway was tested using a Fisher’s exact test per
grouping. Change determined from the per-metabolite ttests (p < 0.05) was classified according to direction of
change from control, i.e., up, down, and unchanged.
Pathway analysis

Pathway analysis was conducted in MetaboAnalyst (2.0;
last accessed April 2013) using the Human Metabolon
Database compound IDs to map to the 80 KEGG human
reference pathways. The metabolites were ranked according to the t-test result. The Global Test for concerted change and the impact factor were calculated for
these pathways. The impact factor used ‘betweenness’
centrality as the measure of impact, thus if altered,
those molecules which act as hubs within a pathway
contribute more strongly to the impact factor. Further
functional analysis was conducted using the Ingenuity
Pathway Analysis (IPA) core analysis of metabolites
(QIAGEN, Redwood City, CA, USA; last accessed
September 2014) is based on the Biocyc pathways and
the proprietary Ingenuity knowledgebase. We used a pvalue threshold of 0.05 and the set of all endogenous compounds as the reference group for the Fisher’s exact tests.
The Human Metabolon Database number, the KEGG
compound ID, or the PubChem ID numbers were used,
with that order of preference, to map the metabolites to
the IPA knowledgebase. Interactions from both experimentally validated and high confidence predictions were
used. No restrictions were made on cell type or species.

Results
Metabolomic profile of platinum sensitive A2780 and
resistant C200 cells lines

We performed a global metabolic analysis of the platinum sensitive ovarian cancer cell line A2780 and its isogeneic platinum resistant derivative cell line C200 [23].
For these cell lines 288 metabolites were identified. The
missing value rate was only 10.6% per sample on average
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(range: 8.3%-13.2%). The PLS-DA combines features
from principle component analysis and multiple regression and transforms a large number of potentially correlated variables into a smaller number of orthogonal
variables (i.e. component 1, component 2) that discriminates between classes. We observed that a clear separation of A2780 and C200 cells can be achieved
indicating that unique metabolite profiles are present
for the sensitive and resistant cell lines (Figure 1A). The
z-score plot showcases the extent of the metabolite alterations, where the intensities of the resistant C200
cells (red dots, z-score range −17 to +130, truncated at
25) are plotted relative to the distribution of the intensities in the sensitive A2780 cells (blue dots, Figure 1B).
Each dot in the z-score plot represents 1 observation
per single metabolite (rows), standardized against the
mean and standard deviation of the A2780 cells and organized by major metabolic pathway. Formal testing,
per-metabolite by two-sample t-tests, shows that there
are 179 metabolites with differences in mean intensity
at p < 0.05 (Additional file 1: Table S1). Of these, 70
were at higher concentrations and 109 were at lower
concentration in the resistant C200, compared to the
sensitive A2780 cells. The heatmap (Figure 1C) depicts
the most altered metabolites (t-test p < 0.01). Here the
metabolites (rows) are ordered by super-pathway and
then by direction of change.
Collection of metabolites by super-pathway, revealed
that most altered metabolites belonged to the lipid
(36.87%) and amino acid (25.7%) pathways, followed by
the carbohydrate (12.29%), nucleotide (8.94%), peptide
(7.26%), cofactors and vitamins (4.47%), energy (2.79%),
and xenobiotics (1.68%) (Figure 2). Metabolites were further classified into sub-pathways. Lipids showed the most
changes in long chain fatty acids (24.24%) and lysolipids
(21.21%) (Figure 2A). Metabolites of the cysteine, methionine, taurine (19.57%) and alanine-aspartate and glutamate
(13.04% each) were most affected in the amino acids superpathway (Figure 2B). Carbohydrate metabolites most
altered belonged to the sub-pathways of nucleotide sugars
and pentose (36.36%) and glycolysis-gluconeogenesis
(36.36%) (Figure 2C). Purine metabolism–adenine containing (43.75%) sub-pathways were largely altered in the
nucleotide super-pathways (Figure 2D). Dipeptides
(84.62%) were most numerously changed in peptide
pathway (Figure 2E). In energy metabolism, Krebs cycle
metabolites (80%) were the most altered (Figure 2F).
Amongst cofactors and vitamins, nicotinates (37.5%) were
more altered (Figure 2G), while chemicals (66.67%) were
more changed in the xenobiotic mediated metabolites
(Figure 2H). Overall, the platinum sensitive A2780 and
resistant C200 ovarian cancer cell lines showed distinct
metabolite changes associated with various metabolic
pathways.
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Figure 1 Metabolomics profiling of platinum sensitive A2780 and resistant C200 cell lines. (A) Partial least squares discriminant analysis
(PLS-DA) score plot shows clear separation of metabolic profile of platinum sensitive A2780 and resistant C200. (B) Z-score plot of C200 metabolite
intensities (RED, z-score range −18 to +174, truncated at 25) against A2780 metabolites (BLUE), taken as mean. Each dot represents 1 metabolite per
observation. (C) Unsupervised hierarchical clustering of signature metabolites (N = 179) that separate A2780 vs C200 cells (t-test, p < 0.05). Yellow and
blue indicate increased and decreased levels, respectively, with coloring for each metabolite relative to its mean observed intensity.

Metabolic pathway analysis of altered profiles

To understand the functional role of the profile alterations, the KEGG metabolic library [24] was analyzed
using MetaboAnalyst [25] (Figure 3). Of the 288 measured metabolites, 73% were able to be mapped to the
KEGG pathways. Both the correlated change of metabolite intensities within pathway between condition (Global
Test) [26], and the impact of the changed metabolites on
the function of the pathway through alterations in critical
junction points of the pathway (relative betweenness centrality) were assessed. Results of each of the 80 human
pathways of KEGG were simultaneously plotted (Figure 3A)
to show the most significant pathways in terms of Global
Test p-value (vertical axis, shades of red) and impact (horizontal axis, circle diameter), Additional file 2: Table S2 [24].
The top 6 pathways that emerged with low p-values (−LN
(P) > 15) and with “high” impact (impact > 0.3) are indicated

in Figure 3A: 1) cysteine and methionine; 2) D-arginine and
ornithine; 3) starch and sucrose; 4) amino sugar and nucleotide; 5) pyrimidine; and 6) glutathione (GSH) pathways.
The log mean concentrations of the metabolites considered under each pathway are depicted in Figure 3B-F.
The significantly altered metabolites categorized under
cysteine and methionine metabolism included: 5methylthioadenosine, cystathione, cysteine, cysteine sulfunic acid, cysteine and methionine that were present in
reduced levels in the resistant C200 cells compared to
A2780 cells; while alanine, aspartate, reduced GSH, Sformyl-L-methionine and pyruvate were increased in
C200 cells (Figure 3B). Arginine was reduced and ornithine levels were at increased levels in the resistant cells
(Figure 3C). Most of the metabolites grouped under starch
and sugar metabolism and amino sugar and nucleotide
metabolism were same as earlier pathway categories
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Figure 2 Metabolic super-pathways and sub-pathways altered in platinum sensitive A2780 and resistant C200 cell lines. To describe the
altered metabolites observed in this study, each is classified into major classes of (A) Lipids, (B) Amino acids, (C) Carbohydrate, (D) Nucleotide,
(E) Peptide, (F) Vitamins and co-factors, (G) Energy and (H) xenobiotics, then further into sub-pathways. CoA: Coenzyme A; FA: fatty acids;
SAM: S-adenosylmethionine.

(fructose, glucose, glucose 1-phosphate, glucose 6phosphate, N-acetyl neuraminate and UDP-glucunorate),
and were decreased in the resistant C200 cells, except
xylose and N-acetyl glucosamine, which were increased
(Figure 3D and E). Pyrimidine metabolites 5,6-dihydro uracil, beta-alanine, glutamine, urea, uridine 5-diphosphate and
uridine 5-triphosphate were significantly lower in resistant
C200 cells while cytidine, thymidine 5-monophosphate and
uridine 3,5-monophosphate were significantly higher compared to sensitive A2780 cells (Figure 3F). Metabolites of
the GSH metabolism, including cysteine, cysteinylglycine,
reduced GSH and oxidized GSH, which are downstream
products of the cysteine metabolism, were at higher concentrations in the C200 cells (Figure 3G). Metabolite products
from the polyamine biosynthesis included putrescine,
which was increased, and spermidine and spermine, which

were decreased in the resistant C200 compared to the sensitive A2780 cells (Figure 3G). Thus, the most altered
metabolic pathways shared many common metabolites,
suggesting a link between the important altered metabolic
pathways.
Ingenuity pathway analysis (IPA)

To gain biologically related molecule networks, 217 of
288 molecules were mapped into the IPA knowledgebase. The top 5 canonical pathways observed were
1) super-pathway of methionine degradation; 2) cysteine
biosynthesis III; 3) urea cycle; 4) taurine biosynthesis;
and 5) citrulline-nitric oxide cycle (Figure 4A; Additional
file 3: Table S3). The methionine degradation and cysteine biosynthesis pathway metabolite alterations align
with the cysteine and methionine metabolism pathway
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(See figure on previous page.)
Figure 3 MetaboAnalyst analysis. (A) Human pathways of Kyoto Encyclopedia of Genes and Genomes (KEGG) (80) are simultaneously plotted
to show the most significant pathways in terms of Global Test p-value (vertical axis, shades of red) and impact (horizontal axis, circle diameter).
The top 6 pathways that arise with low p-values (−LN(P) > 15) and with “high” impact (impact > 0.3) are indicated in the table. Log mean of the
individual metabolites altered within each metabolic pathway are represented as bar graphs. (B) Cysteine and methionine pathway; (C) D-arginine
and ornithine metabolism; (D) starch and sucrose metabolism; (E) amino sugar and nucleotide sugar metabolism; (F) pyrimidine metabolism; and
(G) glutathione metabolism. *p < 0.05. Abbreviations: Comps: compounds; FDR: false discovery rate.

that had the lowest p-value and the most impact value
in the MetaboAnalyst analysis (Figure 3), further supporting that it could be the most significant metabolic
pathway in our system. The top 5 altered bio-functions
in terms of molecular and cellular functions were cell
signaling (p-value range: < 0.0001 to 0.0335); molecular
transport (p-value range: < 0.0001 to 0.0409); vitamin
and mineral metabolism (p-value range: < 0.0001 to
0.0386); lipid metabolism (p-value range: < 0.0001 to
0.0386), and small molecule biochemistry (p-value range: <
0.0001 to 0.0386) (Additional file 3: Table S3).

IPA network analysis, using the proprietary Ingenuity
knowledgebase, constructs networks of altered molecules which are not limited by canonical pathway
boundaries. Eleven networks were constructed as reported
in Additional file 3: Table S3. The top network uses 19 molecules and focuses on carbohydrate metabolism, energy
production, and small molecule biochemistry (Figure 4B).
Containing metabolites like glucose-6-phosphate (down in
C200), pyruvate (high in C200) and citric acid (high in
C200) from energy metabolism pathway and various lipids
like oleic acid, malic acid, palmitate, linoleic acid, etc. (all

Figure 4 Ingenuity Pathway Analysis (IPA) analysis. (A) Top 5 canonical pathways enriched by observed metabolite alterations. (B) The top
network includes aspects of carbohydrate metabolism, energy production, and small molecule biochemistry. Networks, constructed from the IPA
knowledgebase by connecting the altered molecules, are not limited by canonical pathway boundaries. Abbreviations: ERK 1/2: extracellular-signal-related
kinases 1 and 2; CPT1:.carnitine palmitoyltransferase 1; ACAC: acetyl CoA carboxylase; sPLA2: soluble phospholipase A2; PmCa: plasma membrane calcium
ATPase; HMGCoA: 3-hydroxy-3-methyl-glutaryl-CoA; Acox: acyl CoA; Ces: cholesterol esters.
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low in C200); it has hubs at the signaling molecule
extracellular-signal-related kinases1/2 (ERK) (Figure 4B).
ERKs participate in the Ras-Raf-MEK-ERK signaling pathway and is reported to be up-regulated in almost all cancers
[27]. Network 2 uses 20 molecules and focuses on drug metabolism, molecular transport, and small molecule biochemistry. Most of the metabolites in this network are
derived from the methionine-cysteine metabolism and related to amino acids that centralize on GSH (up in C200)
and Akt as the signaling molecule (Additional file 4: Figure
S1), that is a constituent of one of the most dysfunctional
signal transduction pathways described in various cancers
[28]. Network 3 included 16 metabolites of pyrimidine metabolism to generate a linkage of nucleic acid metabolism
and small molecule biochemistry (Additional file 5: Figure
S2, Additional file 3: Table S3). The signaling hubs were calcium ions and epidermal growth factor receptor. Network
4 uses 15 molecules and focuses on free radical scavenging,
lipid metabolism and small molecule biochemistry. Metabolites in this network are from methionine metabolism,
phospholipids and nucleic acid metabolism, superoxide and
GSH (Additional file 6: Figure S3). Network 5 with 12 metabolites was convened as carbohydrate metabolism, lipid
metabolism and molecular transport. All metabolites except
sn-glycerol3-phosphate were lower in C200 cells, including
the central molecule, D-glucose. The lipids stearic acid and
cholesterol were also lower in the C200 cells. The network
revealed connections leading to pro-oncogenic signaling
molecules like mammalian target of rapamycin complex 1
(mTORC1), c-Jun N-terminal kinases, VEGF and Peroxisome proliferator activator receptor (Additional file 7:
Figure S4). Overall, the networks analysis suggests that altered metabolites of energy metabolism, methionine metabolism and lipids are linked with tumor promoting signaling
molecules.

Discussion
Our metabolomics analysis demonstrated that distinct
metabolic profiles can be detected for platinum sensitive
A2780 and resistant C200 ovarian cancer cells (Figure 1).
The altered metabolites encompassed all major molecular categories and metabolic pathways (Figure 2) and appeared to be inter-connected. Arranging the significantly
altered metabolites from the KEGG metabolic pathways
and the top canonical pathways from IPA into a single
map revealed a high level of connectivity and interdependence among the pathways (Figure 5). For example, the glycolysis-to-citrate cycle not only generates
adenosine triphosphate, which is required for all biosynthetic pathways to occur, but also synthesizes essential
metabolites such as glyceraldehyde 3-phosphate, a precursor for the generation of amino acid serine. Serine
then enters the methionine pathway to produce cysteine,
leading to GSH production. GSH, apart from protecting
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cells from oxidative stress, also maintains the NADPH/
NADP+ ratio, which is required by the folate cycle and
nucleotide biosynthesis, among others [29]. Cysteine can
be converted back to pyruvate by transamination [29].
The glycolysis-to–pentose phosphate pathway metabolites are also the sources for precursors of nucleotides
and modifiers of lipids, purine and protein modifications. Thus the metabolism of a cell runs its own ‘cycle
of life’ in unison that sustains the cell function and
growth. Most of the altered metabolites participate in
more than 1 pathway in significant ways and the change
in that 1 metabolite could have a resonating effect for
other pathways.
Collectively the largely significant altered metabolites
belonged to the methionine-cysteine metabolism and
one of its downstream metabolic tributaries of the GSH
pathway (Figure 6). The methionine pathway along with
folate and transulfuration pathways constitutes the onecarbon metabolism [29,30]. The one-carbon metabolism
is known as a metabolic integrator that assimilates products from the glucose pathway and amino acids to fulfill
integral and essential cellular biosynthesis for biological
functions, such as cellular turnover and proliferation.
The one-carbon metabolism pathway has also been investigated as a major contributor to the process of oncogenesis [30]. Studies have shown that methionine levels
are directly involved in promoting proliferation of cancer
cells [31] and in protecting the cancer cells against chemotherapeutic drugs like Fluorouracil [32]. Methionine
deprivation has been shown to inhibit tumor cell growth
in various cancers both in in vitro and in vivo models
along with chemo-sensitizing cancer cells [33-36]. We
observed decreased levels of methionine in resistant
C200 cells, which could indicate its increased utilization
(Figure 3B), and could suggest the presence of ‘methionine dependency’ in the resistant cells. Methioninedependency is defined as inability or reduced ability of
cancer cells to proliferate even when methionine is replaced by its precursor homocysteine, this phenotype
has been demonstrated in several cancers like prostate
and lymphoma [37,38]. Since methionine is an integral
participant of various metabolic pathways, the exact
mechanism underlying methionine-dependence of various cancer cells has been difficult to elucidate [37].
Homocysteine is an important metabolite of the methionine pathway that is coupled with the folate cycle and
on gaining a methyl group from methyl THF converts
back to methionine [29,39]. Methionine can also be produced by the salvage pathway via the crucial enzyme
methylthioadenosine phosphorylase (MTAP), which has
been shown to be deleted in various cancers [40].
Methylthioadenosine, the substrate for MTAP, was observed to be present in lower quantities in C200 cells
compared to A2780 (Figure 3B), which could again
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Figure 5 Interconnected altered metabolic pathways. Altered metabolites from the top 6 MetaboAnalyst analysis and the top 3 Ingenuity
Pathway Analysis are charted within their own metabolic pathway along with their cross-participation in other metabolic pathways. RED text
metabolites represent elevated mean intensity in C200 cells compared to A2780 cells, whereas GREEN text represent reduced intensity.
Abbreviations: CoA: Coenzyme A; THF: tetrahydrofolate; GSH: reduced glutathione; GSSH: oxidized glutathione; UDP: uridine diphosphate.

suggest use and diversion of methionine to other pathway end-product metabolites like GSH or putrescine
(discussed below), rather than the normal metabolic
cycle. Homocysteine through transsulfuration reactions
also gives rise to cysteine. One of the most important
roles for cysteine is to act as the limiting factor for synthesis of the antioxidant GSH [39,41,42]. GSH is the
main endogenous antioxidant and protects the cells
from metabolic stresses by nonenzymatically reducing
substances like peroxides and free radicals and maintaining an intracellular reducing environment. It also activates GSH s-transferase and detoxifies xenobiotics and
other cell damaging compounds [42]. GSH has been
established as a protective mechanism against the increased oxidative stress encountered by the cancer cells
[42,43], which has been implicated as a contributing factor to chemoresistance development in cancer cells [41].
GSH is present in 2 forms: the reduced and the oxidized
GSH disulfide forms. C200 cells displayed higher levels
of both forms of GSH with the oxidized form being
higher than the reduced form (Figure 3G). This could
indicate a higher level of oxidative stress in the C200
cells and a very active GSH mediated antioxidant system
that is offering added protection to the cells. Thus is our
system, the lowered methionine levels could also

indicate its eventual utilization to maintain the high
levels of GSH observed in the C200, as a means to encounter the assault of chemotherapeutic drugs.
A central metabolite S-adenosylmethionine (SAM) from
the methionine pathway, acts as a donor for methylation
reactions involving methylation of histones, DNA, RNA
and all general protein methylations [39,44], and also participates in biosynthesis of phosphatidylcholine, the major
component of cell membranes, by forming the polar head
group with choline [30]. Methylation processes have been
widely implicated in cancer progression, including ovarian
[45,46]. Aberrant methylation has also been proposed as
a contributing factor for acquisition of chemoresistance,
especially in resistance against DNA-damaging platinum drugs [47,48]. Recently, a cisplatin-resistant cell
line derived from the sensitive A2780 ovarian cancer
cell lines were shown to preferentially select for DNAhypermethylation and the obtained methylated gene signature was found to partially hold validation in a small
subset of patient relapsed ovarian tumors [49]. Thus it
is possible that the chemoresistance in C200 ovarian
cancer cells could be a result of increased methylation
of selective genes, which could be reflected in its altered
metabolism. SAM also provides methyl groups for biosynthesis of polyamines, a vital class of products
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Figure 6 Methionine metabolism pathway. A bio-chart of the methionine metabolism pathway and the related pathways of folate, glutathione and
polyamine biosynthesis. RED text metabolites represent elevated mean intensity in C200 cells compared to A2780 cells, whereas GREEN text represent
reduced intensity. The catalyzing enzymes are texted BROWN. BLUE arrows and text convey the requirement of that pathway metabolite towards the
indicated macromolecule synthesis. Abbreviations: DHF: dihydrofolate; THF: tetrahydrofolate; f-THF: formate-THF; m-THF: methylene-THF; SAM:
S-adenosylmethionine; SAH: S-adenosylhomocysteine; CH3: methyl group; GSH: glutathione, GSSG: oxidized glutathione.

involved in cell proliferation, and have been shown to be
increased during malignancy [50]. Polyamines include putrescine and its derivatives spermidine and spermine,
which are synthesized from ornithine and shown to be required for proliferation [50-52]. On one hand, inhibition
of polyamine synthesis has been shown to inhibit cancer
cells, but on the other hand recent studies have reported
decreased levels of spermine as a metabolic biomarker for
cancer cells [50,53]. We observed an increased level of putrescine and decreased levels of spermine and spermidine
(Figure 3G). This could either indicate a block after putrescine formation or increased utilization of these metabolites. Ornithine decarboxylase (ODC) is the first
enzyme required for polyamine synthesis and is regulated by Myc oncogene [50,54]. Induction of spermidine/spermine N1-acetyltransferase 1(SAT1), the key
enzyme regulating catabolism of polyamines has been
reported to result in decreased spermine and spermidine and increased putrescine levels [55], similar to our
observation in C200 cells (Figure 3G). ODC and SAT1
have been shown to be overexpressed in neoplastic
prostate tissue [56]. Platinum drugs have also been
shown to regulate polyamine metabolism enzymes including SAT1 [18]. Thus acquisition of platinum resistance in C200 cells could be related to perturbations in
the enzymatic makeup of polyamine metabolism.

Our observations are similar to other studies where
the altered methionine pathway has been advocated to
play a role in ovarian and other cancers and its metabolites presented as biomarkers. Alteration of methionine
pathway was suggested early in ovarian cancer [57], where
accumulated homocysteine in ascites was an indicator of
malignancy. A recent study has shown cisplatin treatment
of embryonic mouse cells to induce significant changes in
the methionine degradation pathway, including GSH and
polyamine metabolism, along with other methionine associated pathways [18]. Sarcosine (n-methylglycine), a product of the methionine degradation pathway was reported
as a biomarker in urine of metastatic prostate cancer patients [19]. Comparison of metabolites from early recurrence (within 2 years of surgery) and recurrence free
(more than 5 years) prostate cancer patients found elevated products of methionine catabolism in serum, which
included sarcosine, cysteine, cystathionine and homocysteine [58]. Targeting of the methionine pathway is being actively investigated in cancer therapeutics. Targeting the
epigenetic status by inhibiting methylation of various
genes in tumors is one of the earliest and most pursued
chemotherapeutic approaches [59-61]. SAM-mediated
methylation and polyamine synthesis is being actively investigated in preclinical studies of various cancers [53,62].
Inhibition of GSH activity is also a major area under
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consideration for specific targeting of chemoresistance
[42]. Thus the methionine pathway metabolites appear
to have the potential to act as biomarkers specifically
for metastatic or recurrent tumors. Together, with the
observation that most recurrent tumors are also chemoresistant and our findings, surfacing of the methionine pathway as an indicator of chemoresistance in
ovarian cancer is significant. Thus, an in-depth analysis
of the methionine metabolism encompassing and integrating the levels of input, intermediate and outcome
metabolites flux, along with the expression and activation status of the enzymes catalyzing these reactions
will provide a complete picture in understanding the
functional significance of this pathway in platinum
chemoresistance of ovarian cancer.
While lipids were the most altered class of compounds (36.87%) observed between the resistant and
sensitive cell lines, they were not well represented in the
KEGG pathways. However, 78% of the lipids had at least
1 identifier recognizable by IPA where lipid metabolism
was the fourth altered biofunction. Additionally, all of
the top 5 networks had substantial participation of lipid
metabolites, related enzymes and downstream effectors.
Approximately 70% of the lipids were decreased in
C200 cells, which could be suggestive of a decreased
turnover or a decrease in the metabolism of membrane
lipids. Decreased circulating phospholipids (plasmenylphosphoethanolamine and lysophosphadylcholine) and
increased levels of lysophosphatidic acid (LPA) have
been proposed as biomarkers for ovarian cancer [63,64].
LPA has been shown to be a potent mitogen for ovarian
cancer cells and are found in increased amount within
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ascites [63]. Plasmenylphosphoethanolamine can act as
an antioxidant and its absence may be a consequence of
a higher oxidative environment associated with chemoresistant cells. Lysophosphadylcholine is a main
membrane component and could be utilized as a building block for increased proliferation of cancer cells [63].
The largest group affected was the long chain fatty
acids, which included palmitate, oleate, stearate, etc.
(Figure 7). Alternatively, since fatty acids are the major
building blocks for the synthesis of triacylglycerides,
which are mainly used for energy storage, this could
also indicate an increased breakdown of the fatty acids
by the mitochondria for energy production. The IPA
network analysis projected energy metabolism and lipid
metabolism metabolites as contributors in 3 of the 5 top
networks (Figures 4B and Additional file 7: Figure S4;
Additional file 3: Table S3). A closer look at the involved
molecules supports an altered energy metabolism between the resistant C200 and sensitive A2780 cells. The
C200 cells have higher levels of metabolites from the
tricarboxylic acidcycle (pyruvate, citric acid and succinic
acid) and lower fatty acids (palmitic, oleic and linoleic
acid) and links to the enzymes from the respective pathways (tricarboxylic acid cycle: aconitase, succinate dehydrogenase, lactate dehydrogenase; fatty acid oxidation:
Carnitine palmitoyltransferase-1, Acetyl CoA Carboxylase)
(Figure 6). Therefore the lower levels of overall lipids may
be indicative of either decreased biosynthesis or increased
utilization of lipids. This could suggest a further alteration
in the energy metabolism of the chemoresistant cells,
along with the already altered metabolism established in
cancer cells [65].

Figure 7 Long chain fatty acid levels. Log10 mean of the significantly (p < 0.05) altered individual long chain fatty acids and their metabolites
are represented as bar graphs.
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Conclusions
The altered metabolism of cancer cells has been well
established. Our data shows that platinum sensitive and
resistant ovarian cancer cells can be distinguished based
on their metabolite profiles. This suggests that chemoresistance is associated with its own set of metabolic
changes that can be exploited for biomarker and targeted therapeutic approaches. Based on our data, we
propose the altered methionine pathway metabolites as
the potential biomarkers for platinum resistance in ovarian cancer cells. Most of these metabolites are measurable in body fluids like urine or serum, which would
make their translation into clinical practice easier, once
they have been extensively validated in subsets of ovarian
cancer patients. Although our study is limited by using an
isolated in vitro cell line system, we observed alterations in
metabolites similar to those reported to be associated with
malignancy, specifically metastatic and recurrent tumors.
While our data await further validation, a comprehensive
analysis of the altered pathways may not only provide biomarkers of chemoresistance but can also provide clues of
the biology underlying platinum resistance in ovarian cancer cells and offer plausible therapeutic targets to specifically target chemoresistance
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Additional file 1: Table S1. Spreadsheet file of all raw metabolite data.
Additional file 2: Table S2. Spreadsheet file of MetaboAnalyst
analysis results.
Additional file 3: Table S3. Spreadsheet file of Ingenuity Pathway
Analysis core analysis results.
Additional file 4: Figure S1. Ingenuity Pathway Analysis (IPA) network
2. The second network contains components of drug metabolism,
molecular transport, and small molecule biochemistry. Constructed from
the IPA knowledgebase using altered molecules, these networks are not
limited by canonical pathway boundaries. Abbreviations: ALT : alanine
amino transferase; CYP: cytochrome P450; GABA: gamma –aminobutyric
acid; HDL: high- density lipoprotein; LDL: low density lipoprotein; Sod:
superoxide dismutase; Ggt: gamma-glutamyl transferase; Na: Sodium.
Additional file 5: Figure S2. Ingenuity Pathway Analysis (IPA) network 3.
The third network contains components of nucleic acid metabolism and
small molecule biochemistry. Constructed from the IPA knowledgebase
using altered molecules, these networks are not limited by canonical
pathway boundaries. Abbreviations: ITLN1: interlectin 1; CHRNA1: cholinergic
receptor, nicotin alpha 1; Ca: calcium; PKC: protein kinase C; DuoX1: dual
oxidase 1; EGFR: epidermal growth factor receptor 1; IFNG: interferon
gamma; THOP1: human endopeptidase 1; APOBEC: DNA cytosine
deaminase; AICDA: activation induced cytidine deaminase; CDA:
cytidine deaminase.
Additional file 6: Figure S3. Ingenuity Pathway Analysis (IPA) network
4. The fourth network contains components of free radical scavenging,
lipid metabolism and small molecule biochemistry. Constructed from the
IPA knowledgebase using altered molecules, these networks are not
limited by canonical pathway boundaries. Abbreviations: Cu: copper;
UDP: uridine diphosphate; MTUS1: mitochondrial tumor suppressor 1;
NDUFS1: NADH-ubiquinone oxidoreductase iron-sulfur protein 1;
CDKN1A: cyclin dependent kinase inhibitor 1A; CYP2C8: cytochrome 2C8;
SLC22A6: solute carrier family 22 member 6.
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Additional file 7: Figure S4. Ingenuity Pathway Analysis (IPA) network
5. The fifth network contains components of carbohydrate metabolism,
lipid metabolism and molecular transport. Constructed from the IPA
knowledgebase using altered molecules, these networks are not limited
by canonical pathway boundaries. Abbreviations: DPP4: dipeptidyl
peptidase 4; VEGF: vascular endothelial growth factor; MTORC1:
mammalian target of rapamycin complex1; JNK: c-jun N-terminal kinase;
PPARA: peroxisome proliferator-activated receptor alpha; IDH1: isocitrate
dehydrogenase 1; MOGAT2:acyl CoA: monoacylglycerol acyltransferase;
TALDO1: transaldolase1; FBP2: phosphofruckokinase 2; CCK: cholecystokinin;
PFKFB1: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4; HSD11B1:
11-beta-hydroxysteroid dehydrogenase type 1; TKTL1: transketolase 1;
ATP5G2: ATP synthase; PL1N2: perilipin 2; CA5A: carbonic anhydrase VA.
Abbreviations
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